The same effect was confirmed also in the ErbB2-positive breast cancer cell line BT-474 [337], supporting the notion that NRF2 inhibition with RNAi might be a therapeutic strategy to limit tumor growth and enhance sensitivity to taxane-based chemotherapy. Here, ERBB2 is linked to breast cancer.